Emcure Pharma IPO: Shares List 31% Higher in 2024

Listing day recap: a 31% debut premium

Emcure Pharmaceuticals Ltd made a strong stock market debut on Wednesday, listing at ₹1,325.05 on both the NSE and BSE. The listing price implied a 31.45% premium over the final issue price of ₹1,008 per share. Reports noted that the stock moved higher after listing, touching around ₹1,384 on the BSE and ₹1,385 on the NSE. The listing performance was widely linked to robust investor demand seen during the IPO window. Emcure is described as an Indian pharmaceutical company with a portfolio spanning multiple therapeutic categories and a global distribution footprint.

What investors saw on the screen in early trade

The listing was not a one-off spike in the first print. After opening at ₹1,325.05, the stock traded higher through the session and was reported up as much as 37.30% to ₹1,384 on the BSE and 37.40% to ₹1,385 on the NSE. Market commentary also pointed to the listing being broadly in line with pre-listing expectations. One report referenced the grey market premium (GMP) at about ₹300, implying an indicative listing near ₹1,308 per share, around 29.76% over the issue price. The stock’s early strength was also discussed alongside another listing on the same day, Bansal Wire Industries.

IPO timeline and pricing details

Emcure’s IPO opened for bidding on Wednesday, 3 July 2024, and closed on Friday, 5 July 2024. The price band for the issue was fixed at ₹960 to ₹1,008 per share, with the final issue price set at ₹1,008. The face value was ₹10 per share, and the lot size was 14 shares. These pricing details framed the listing-day gains, with the opening trade delivering an immediate premium to the offer price.

Size of the issue and key demand indicators

The total IPO size was reported at ₹1,952.03 crore. Another report described the Pune-based company as raising about ₹1,952 crore through the IPO route. Subscription data cited in the provided text indicated the public issue was subscribed 67.8 times during the bidding period. A market segment split mentioned total subscription around 67.8 times, with NII at 48.3 times and QIB at 195 times.

Anchor book and use-of-proceeds points highlighted

A transcript segment stated the company raised ₹582 crore from 48 anchor investors. It also described the IPO as comprising roughly ₹800 crore of OFS and about ₹1,151 crore, alongside a stated plan to reduce around ₹600 crore. The same segment framed these points as part of what investors were assessing after a strong listing, with focus on how proceeds and balance sheet actions could shape the company’s post-listing trajectory.

How the business was positioned by market commentary

News coverage characterised Emcure as having a strong presence in women’s healthcare and HIV treatments, which was cited as an investor draw in a busy IPO market. It was also described as a Bain Capital-backed company. Another report noted that in 2024 it was the first drugmaker to go public, in an IPO market where more than 100 companies had raised over $1.6 billion so far that year. These context points were used to explain why the listing was closely tracked.

Later snapshots: price updates and volatility markers

Separate market snapshots in the provided text show Emcure’s shares at different points in time. One update stated the share price moved up by 1.42% from a previous close of ₹1,438.00 to a last traded price of ₹1,458.40. Another snapshot, dated 02-Dec-2025 16:00:00 IST, showed EMCURE at ₹1,385.50, down ₹48.60 or 3.39%, with a close listed at ₹1,434.10 and open at ₹1,433.00. A performance table excerpt showed 1 Day at 1.42% and 1 Week at -4.12%.

A separate “Invest Now” line also listed an intraday High of ₹1,932.00, Open of ₹1,794.83, and Low of ₹1,620.00 for a 1D view, without a visible date tag in the provided text. An “intraday fact check” line stated that since listing, only 3.1% of trading sessions saw intraday gains higher than 5%. Together, these datapoints suggest investors have seen both sharp up-moves and drawdowns across the stock’s listed life.

Key numbers table

Market impact and what to watch

The immediate market impact was clear: the stock delivered over 30% listing gains against the issue price and extended those gains intraday to roughly 37% at the session high. Trading activity was also highlighted, with a line noting that on the NSE, over 98.99 lakh shares changed hands at the counter “till now” in the referenced update. For investors tracking the stock beyond listing day, the later price snapshots and the “3.1% sessions above 5% intraday gains” statistic provide a quick lens on volatility and trading behaviour since listing.

Conclusion

Emcure Pharmaceuticals’ debut at ₹1,325.05, up 31.45% from ₹1,008, stood out among 2024 listings and followed a heavily subscribed ₹1,952.03 crore issue. The stock’s post-listing swing to around ₹1,385 on day one and the later price snapshots underline that market interest has remained active. Investors will continue to track updates around trading performance and any reported balance-sheet actions referenced in the IPO commentary.